58 related articles for article (PubMed ID: 24273152)
1. Changing patterns of use of osteoporosis medications in the years after launch: implications for comparative effectiveness research.
Reams BD; O'Malley CD; Critchlow CW; Lauffenburger JC; Brookhart MA
Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):251-60. PubMed ID: 24273152
[TBL] [Abstract][Full Text] [Related]
2. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development.
Schneeweiss S; Gagne JJ; Glynn RJ; Ruhl M; Rassen JA
Clin Pharmacol Ther; 2011 Dec; 90(6):777-90. PubMed ID: 22048230
[TBL] [Abstract][Full Text] [Related]
3. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
4. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
[TBL] [Abstract][Full Text] [Related]
5. Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007).
Hiligsmann M; Bruyère O; Roberfroid D; Dubois C; Parmentier Y; Carton J; Detilleux J; Gillet P; Reginster JY
Arthritis Care Res (Hoboken); 2012 May; 64(5):744-50. PubMed ID: 22238220
[TBL] [Abstract][Full Text] [Related]
6. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
[TBL] [Abstract][Full Text] [Related]
7. Patterns of osteoporosis treatment change and treatment discontinuation among commercial and Medicare Advantage Prescription Drug members in a national health plan.
Xu Y; Viswanathan HN; Ward MA; Clay B; Adams JL; Stolshek BS; Kallich JD; Fine S; Saag KG
J Eval Clin Pract; 2013 Feb; 19(1):50-9. PubMed ID: 21914091
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of combination osteoanabolic and antiresorptive therapy for osteoporosis: an update.
Cusano NE; Bilezikian JP
J Comp Eff Res; 2013 Nov; 2(6):511-3. PubMed ID: 24236786
[No Abstract] [Full Text] [Related]
9. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
[TBL] [Abstract][Full Text] [Related]
10. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
11. High-dose corticosteroid exposure and osteoporosis intervention in adults.
Che M; Ettinger B; Nguyen MT; Pressman AR; Johnston J
Ann Allergy Asthma Immunol; 2006 Oct; 97(4):497-501. PubMed ID: 17069105
[TBL] [Abstract][Full Text] [Related]
12. A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis.
Gold DT; Martin BC; Frytak JR; Amonkar MM; Cosman F
Curr Med Res Opin; 2007 Mar; 23(3):585-94. PubMed ID: 17355739
[TBL] [Abstract][Full Text] [Related]
13. Dementia diagnosis and osteoporosis treatment propensity: a population-based nested case-control study.
Knopp-Sihota JA; Cummings GG; Newburn-Cook CV; Homik J; Voaklander D
Geriatr Gerontol Int; 2014 Jan; 14(1):121-9. PubMed ID: 23992035
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Landfeldt E; Lang A; Robbins S; Ström O
Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
[TBL] [Abstract][Full Text] [Related]
15. Factors contributing to compliance with osteoporosis medication.
Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
[TBL] [Abstract][Full Text] [Related]
16. Big data, advanced analytics and the future of comparative effectiveness research.
Berger ML; Doban V
J Comp Eff Res; 2014 Mar; 3(2):167-76. PubMed ID: 24645690
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry.
Coulson KA; Reed G; Gilliam BE; Kremer JM; Pepmueller PH
J Clin Rheumatol; 2009 Jun; 15(4):155-60. PubMed ID: 19363452
[TBL] [Abstract][Full Text] [Related]
18. Prescriptions for vitamin D among patients taking antiresorptive agents in Canada.
Hanley DA; Zhang Q; Meilleur MC; Mavros P; Sen SS
Curr Med Res Opin; 2007 Jun; 23(6):1473-80. PubMed ID: 17559742
[TBL] [Abstract][Full Text] [Related]
19. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S.
Skrepnek GH; Seal B; Tangirala M; Jeffcoat MK; Watts NB; Hay JW
Gen Dent; 2010; 58(6):484-92; quiz 493-4. PubMed ID: 21062718
[TBL] [Abstract][Full Text] [Related]
20. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis.
Cotté FE; Mercier F; De Pouvourville G
Clin Ther; 2008 Dec; 30(12):2410-22. PubMed ID: 19167600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
